Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis. (2021)
Attributed to:
MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1080/1744666x.2021.1967748
PubMed Identifier: 34384327
Publication URI: http://europepmc.org/abstract/MED/34384327
Type: Journal Article/Review
Volume: 17
Parent Publication: Expert review of clinical immunology
Issue: 10
ISSN: 1744-666X